Indivior Pharmaceuticals (INDV) is back in focus after agreeing to acquire Supernus Pharmaceuticals. This move is now reshaping index membership, as Supernus exits the S&P SmallCap 600 and Huron Consulting Group steps in.
At a share price of US$34.47, Indivior Pharmaceuticals has seen short term momentum cool, with the share price down 14.94% over 90 days. However, the 1 year total shareholder return of 37.17% and 5 year total shareholder return of 103.37% indicate that investors have still been rewarded for staying invested as perceptions around its growth prospects and risks have shifted over time.
Scan the market for peers to Indivior Pharmaceuticals that are also moving on fresh catalysts using a curated list of 21 high quality undiscovered gems to see what else is flying under the radar.
Short term weakness and the Supernus deal have pulled Indivior Pharmaceuticals back into the spotlight. Are you seeing a cooler share price, or a business that now prices in very different expectations?
Most Popular Narrative: 32% Undervalued
Against a last close of $34.47, the most followed narrative for Indivior Pharmaceuticals points to a fair value of about $50.83. This implies a sizeable gap that investors now weigh against execution risks and the Supernus acquisition.
The multiyear Indivior Action Agenda, including at least $150 million in annual operating expense savings and a capped 2026 operating budget of $450 million, is intended to materially lower the cost base and support the translation of revenue growth into earnings and cash flow expansion.
See why 5 investors see Indivior Pharmaceuticals as 32% undervalued.
Result: Fair Value of $50.83 (UNDERVALUED)
Still, if SUBLOCADE uptake slows or cost savings from the Indivior Action Agenda disappoint, the Indivior Pharmaceuticals turnaround narrative could look far less compelling.
Find out about the key risks to this Indivior Pharmaceuticals narrative.
Next Steps
Mixed messages on Indivior Pharmaceuticals so far. Act quickly; review both the risks and the brighter spots, then anchor your own stance with 5 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Indivior Pharmaceuticals?
If you stop with Indivior Pharmaceuticals, you risk missing other compelling setups that fit your style and risk profile across sectors and market caps.
- Target stronger downside protection by screening for 30 resilient stocks with low risk scores that keep volatility in check while you focus on the long game.
- Prioritise financial resilience and filter for businesses with a list of solid balance sheet and fundamentals (25 results) so debt and liquidity do not become tomorrow's surprise.
- Hunt for mispriced potential by scanning a 7 elite penny stocks with strong financials that could add controlled punch to a diversified portfolio.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com